TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

Vaccines
BE
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Business Energy and Industrial Strategy: "ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityBusiness Energy and Industrial StrategyScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Business Energy and Industrial Strategy
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Business Energy and Industrial Strategy. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
2.1Bids / Report
64% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 26 active published awards; 25 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityBusiness Energy and Industrial Strategy
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published12 Feb 2021, 17:45 GMT
Last source update12 Feb 2021, 17:45 GMT
Recurring procurementNot published
ClassificationVaccines
Delivery area
BE
OCIDocds-h6vhtk-029301
What is being bought
Procurement of Janssen's vaccine candidate Ad26.COV2-S.
What changed
From the official release history
  1. Status changed to complete
    12 Feb 2021, 17:45 GMT
  2. Official notice release published
    12 Feb 2021, 17:45 GMT
  3. Buyer information updated
    12 Feb 2021, 17:45 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    This contract has been procured using the negotiated procedure without prior publication under regulation 32 of the Public Contracts Regulations 2015 on the basis that the award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to secure priority access to a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)). Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    12 Feb 2021, 17:45 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 15 Jan 2021, 00:00 GMT · £1
Commercial outcome and competition
Awards
JANSSEN PHARMACEUTICA NV
Not published · Not published · active
Contracts
ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE
£1 · signed 15 Jan 2021, 00:00 GMT · active
Bid statistics
bids: 1 (lot 1)
Buyer and organisations in this procedure

Business Energy and Industrial Strategy

Contracting authority GB-FTS-5606
View buyer profile

  • Business Energy and Industrial Strategy
    buyer

    1 Victoria Street, London, UK, SW1H0ET
    VTFContracts@beis.gov.uk

  • Department of Business, Energy and Industrial Strategy
    reviewBody

    1 Victoria Street, London, SW1H 0ET

  • JANSSEN PHARMACEUTICA NV
    supplier

    30 Turnhoutseweg, Beerse, BE, B-2340
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleThe award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid 19 pandemic (Regulation 32(2)(c)).